NantHealth is a new Healthcare Information Services company based in Culver City, California. The Founder is a guy named Patrick Soon-Shiong. The first thing to do is to read about his guy:
https://en.wikipedia.org/wiki/Patrick_Soon-Shiong
Here is an excerpt:
"In 1991, Soon-Shiong left UCLA to start a diabetes and cancer biotechnology firm. This led to the founding in 1997 of APP Pharmaceuticals (APP), which he held 80% of outstanding stock and sold to Fresenius SE for $4.6 billion in July 2008.[13][dead link] Soon-Shiong later founded Abraxis BioScience (maker of the drug Abraxane he co-discovered),[14] a company he sold to Celgene in 2010 in cash-and-stock deal, valued at over $3 billion."
Here is a description of the company:
"We are a leading next-generation, evidence-based, personalized healthcare company focused on enabling our clients to fundamentally change the diagnosis, treatment and pharmacoeconomics of cancer and other critical illnesses. We believe a molecular-driven, systems-based approach to making clinical treatment decisions based on large-scale, real time biometric and phenotypical data will become the standard of care initially for patients with cancer and, ultimately, other critical illnesses. We derive revenue from selling GPS Cancer (our Genomic Proteomic Spectrometry Cancer test, a unique, comprehensive molecular test and decision support solution that measures the proteins present in the patient's tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor & normal samples), to which we obtained exclusive access from an affiliate, and NantOS and NantOS apps to healthcare providers and payors, self-insured employers and biopharmaceutical companies. NantOS and NantOS apps include proprietary methods and algorithms for enabling healthcare providers to make better treatment decisions to improve patient outcomes and lower the cost of care, and allow healthcare payors to ensure that their dependents receive high quality care in a cost effective manner. We believe that as healthcare providers and payors migrate to value-based reimbursement models and implement advances in precision medicine, our offerings position us at the forefront of multiple significant market opportunities."
https://en.wikipedia.org/wiki/Patrick_Soon-Shiong
Here is an excerpt:
"In 1991, Soon-Shiong left UCLA to start a diabetes and cancer biotechnology firm. This led to the founding in 1997 of APP Pharmaceuticals (APP), which he held 80% of outstanding stock and sold to Fresenius SE for $4.6 billion in July 2008.[13][dead link] Soon-Shiong later founded Abraxis BioScience (maker of the drug Abraxane he co-discovered),[14] a company he sold to Celgene in 2010 in cash-and-stock deal, valued at over $3 billion."
Here is a description of the company:
"We are a leading next-generation, evidence-based, personalized healthcare company focused on enabling our clients to fundamentally change the diagnosis, treatment and pharmacoeconomics of cancer and other critical illnesses. We believe a molecular-driven, systems-based approach to making clinical treatment decisions based on large-scale, real time biometric and phenotypical data will become the standard of care initially for patients with cancer and, ultimately, other critical illnesses. We derive revenue from selling GPS Cancer (our Genomic Proteomic Spectrometry Cancer test, a unique, comprehensive molecular test and decision support solution that measures the proteins present in the patient's tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor & normal samples), to which we obtained exclusive access from an affiliate, and NantOS and NantOS apps to healthcare providers and payors, self-insured employers and biopharmaceutical companies. NantOS and NantOS apps include proprietary methods and algorithms for enabling healthcare providers to make better treatment decisions to improve patient outcomes and lower the cost of care, and allow healthcare payors to ensure that their dependents receive high quality care in a cost effective manner. We believe that as healthcare providers and payors migrate to value-based reimbursement models and implement advances in precision medicine, our offerings position us at the forefront of multiple significant market opportunities."
No comments:
Post a Comment